Table 3.
Deletion (grey) or modification (red) of the N-terminal residues in VIP and PACAP analogues can be used to generate receptor-selective peptide antagonists.
| N-Terminal Truncation/Modification | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 10 | 15 | 20 | 25 | 30 | 35 | |||||||||||||||||||||||||||||||
| PACAP38 | H | S | D | G | I | F | T | D | S | Y | S | R | Y | R | K | Q | M | A | V | K | K | Y | L | A | A | V | L | G | K | R | Y | K | Q | R | V | K | N | K |
| PACAP(6–38) | H | S | D | G | I | F | T | D | S | Y | S | R | Y | R | K | Q | M | A | V | K | K | Y | L | A | A | V | L | G | K | R | Y | K | Q | R | V | K | N | K |
| VIP | H | S | D | A | V | F | T | D | N | Y | T | R | L | R | K | Q | M | A | V | K | K | Y | L | N | S | I | L | N | ||||||||||
| PG 97-269 1 | H | F | D | A | V | F | T | N | S | Y | R | K | V | L | K | R | L | S | A | R | K | L | L | Q | D | I | L | |||||||||||
| PG 99-465 2 | H | S | D | A | V | F | T | D | N | Y | T | K | L | R | K | Q | M | A | V | K | K | Y | L | N | S | I | K | K | G | G | T | |||||||